S100A6 as a Marker in Prostate Cancer
Author Information
Author(s): Rehman I, Cross S S, Azzouzi A-R, Catto J W F, Deloulme J C, Larre S, Champigneuille J, Fromont G, Cussenot O, Hamdy F C
Primary Institution: University of Sheffield
Hypothesis
The study investigates the involvement of S100A6 during prostate cancer development and progression.
Conclusion
Loss of S100A6 protein expression is common in prostate cancer development and may occur at an early stage.
Supporting Evidence
- S100A6 was intensely expressed in benign prostate basal cells but absent in malignant cells.
- Loss of S100A6 expression was observed in all cases of adenocarcinoma and metastatic lesions.
- Treatment with 5-Azacytidine reactivated S100A6 mRNA expression in LNCaP cells.
- CpG methylation was identified in the S100A6 promoter region in prostate cancer cell lines.
Takeaway
S100A6 is a protein that is found in healthy prostate cells but is missing in prostate cancer cells, which could help doctors diagnose the disease.
Methodology
The expression of S100A6 was examined in benign, premalignant, malignant, and metastatic prostate tissues using immunohistochemistry and compared with cytokeratin markers.
Limitations
The study primarily focused on specific cell lines and may not represent all prostate cancer types.
Participant Demographics
Patients attending the Urology clinic at three centers, including the University of Sheffield and two French universities.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website